Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-12-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于取得食品生产许可证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the acquisition of a Food Production License by its wholly-owned subsidiary. It details the license content, its validity, and the impact on the company. The document is short (853 characters) and serves as a formal notification of a regulatory approval rather than a financial report or detailed operational disclosure. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-11 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving a drug registration certificate from the national drug regulatory authority. It details the product name, specifications, approval, and potential market impact. There is no financial data, no mention of financial results, no management discussion, no shareholder voting, no regulatory filing of financial nature, and no mention of any report publication. The document is an official announcement regarding a regulatory approval related to the company's product, which is a typical regulatory announcement. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2025-12-01 Chinese
关于实施2025年第二次回购公司股份方案之首次回购股份暨进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's implementation of a share repurchase plan, detailing the first repurchase of shares, prices, quantities, and compliance with relevant regulations. It does not contain financial statements or performance data but focuses on the share buyback activity and regulatory compliance disclosures. This fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2025-11-30 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts signed with a bank, amounts, terms, and the financial status of the guaranteed subsidiaries. The document includes board opinions and cumulative guarantee amounts. It is a regulatory announcement about financing guarantees rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather updates on financing guarantees and related board approvals. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3553 characters, which is consistent with an announcement rather than a full report.
2025-11-28 Chinese
关于第一期员工持股计划存续期即将届满的提示性公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from 普洛药业股份有限公司 regarding the nearing expiration of the first employee stock ownership plan's term. It details the history, extensions, and current status of the employee stock plan, including board meeting approvals and compliance with regulatory requirements. The document does not contain financial statements or detailed financial data but serves as a regulatory disclosure about the employee stock plan's status and extensions. It is not a full report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about a specific corporate action related to employee stock plans. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-25 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 普洛药业股份有限公司 regarding the receipt of a drug registration certificate from the National Medical Products Administration (国家药品监督管理局). It details the product name, specifications, registration classification, approval conclusion, and the impact on the company. The document is short (1144 characters) and focuses on regulatory approval and product registration rather than financial results, management changes, or shareholder information. It does not contain financial statements or detailed financial data. This type of announcement fits best under Regulatory Filings (RNS), as it is a regulatory announcement about product approval and does not match other specific categories like Annual Report, Earnings Release, or Capital Update.
2025-11-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.